Introduction
Recently, overall survival results were published for the aXIs study (Motzer et al. 2013) , a large clinical trial comparing axitinib to sorafenib as second line treatment for patients with advanced or metastatic renal cell carcinoma. although an earlier publication (Rini et al. 2011 ) showed a median progression-free survival (PFs) benefit that favored axitinib (6.7 vs 4.7 months, hazard ratio 0.665; p < 0.0001], the final results showed no difference in overall survival (Os) 3) (hazard ratio [HR] 0.969, p = 0.3744]. since the study did not permit crossover, the authors attempted to explain the negative outcome with this disclaimer, "being able to show a survival advantage is especially challenging when survival post-progression is long, that is, 12 months or longer, because the variability added during a long survival post-progression might dilute the ability to detect statistically significant difference in overall survival (Motzer et al. 2013)." there is a widespread belief in oncology that when postprogression survival is long, we cannot ask trials to sate an overall survival endpoint. an abstract from the 2012 COsa-IPOs (Clinical Oncology society of australiaInternational Psycho-Oncology society) Joint scientific Meeting states, "although improvements in overall survival V. Prasad (*) Medical Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Dr. 10/12N226, Bethesda, MD 20892, usa e-mail: vinayak.prasad@nih.gov a. Vandross Department of Medicine, Yale university school of Medicine, New Haven, Ct, usa power to detect a significant improvement in Os also decreases. If a 3-month PFs benefit passed the threshold of significance (p < 0.05), the probability of detecting an Os benefit decreases dramatically from 33 % when sPP is short (2 months) to 8 % when sPP is long (24 months). However, the central limitation to this paper, as well as, more generally, any justification derived from modeling, is that it rests on an unproven assumption: median sPP is the same in treatment and control arms.
Ideally, empirical data would be able to adjudicate this issue, but empirical studies on this topic have methodological issues. In august 2012, the Decision support unit (Dsu) of the National Institute for Health and Clinical excellence (NICe) performed a systematic review of 19 studies that examined the relationship between progression-free and overall survival in metastatic or advanced cancer (Davis and Cantrell 2012) . the group found wide variability in proffered correlation coefficients between PFs and Os, ranging in size from 0.24 to 0.89. the authors conclude that correlation between PFs and Os is generally tenuous, but may be useful for some specific cancers and some classes of agent. Yet, even this interpretation is generous. another way to look at these data is to examine the range of variability in the PFs to Os correlation. One study (Wilkerson and Fojo 2009) , comparing the PFs to Os in 66 publications, found that for marginal PFs gains (0-2 months), Os could change anywhere from −2 to +8 months. In a review of 18 bevacizumab trials (Ocaña et al. 2011) , the median absolute difference in PFs ranged from +0.4 to +5.9 months (median 1.9), while Os ranged from −1.7 to +7.8 months (mean 1.2). In short, even if the proffered correlations are true, they are just that: correlations (Baker and Kramer 2003 there is an additional and overarching deficiency in investigations of the correlation between PFs and Os. specifically, the trials included in these studies did not always achieve significant findings for both metrics. thus, correlations are being made between one significant outcome (typically PFs) and another outcome, which is not significant (typically Os). Nonsignificant outcomes may be trending toward significance and ultimately valid, but alternatively, they may be distortions of the true outcome. Were the trial to continue or be adequately powered, nonsignificant Os results may remain nonsignificant, or trend toward harm. Because these correlation studies typically include trials with one (but not usually 2) nonsignificant outcomes, these analyses may be further affected by publication or selective reporting bias (Kyzas et al. 2005) . For instance, trials with small PFs benefit, but no or detrimental changes in Os may not be published, published in lesser journals or published only after significant delay (Ioannidis 1998) . trials with little or no change in PFs may be halted, unpublished or missed by meta-analysts, and the effect of these medications on mortality may be unknown. Null median PFs results do not necessarily imply null Os, as was seen in trials of sipuleucel-t (Kantoff et al. 2010 ) and ipilimumab (Hodi et al. 2010) . In short, the trials included in correlation studies of PFs and Os likely represent only a select slice of studies that could capture both outcomes.
The E2100 trial
If the argument of long sPP sounds familiar, it may be because of the bevacizumab e2100 study. the study randomized 722 women with metastatic breast cancer, who had not received cytotoxic therapy, to paclitaxel with or without bevacizumab. the trial famously found a markedly prolonged progression-free survival favoring bevacizumab (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; p < 0.001) but no improvement in overall survival (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; p = 0.16) (Miller et al. 2007) . to make sense of the data, the authors evoked sPP, "Patients with metastatic breast cancer frequently receive multiple therapies during the course of their disease. Data on treatment administered after progression were not collected in this trial, precluding an exploratory analysis of the influence of subsequent therapy on overall survival (Miller et al. 2007) ." the dramatic findings of the e2100 led the us Food and Drug administration (FDa) to grant bevacizumab accelerated approval in combination with paclitaxel for first-line treatment of metastatic breast cancer in 2008. two years later, the results of two additional randomized trials were reported. the avastin Plus Docetaxel (aVaDO) study compared docetaxel with or without bevacizumab at two different doses (7.5 and 15 mg/kg) (Miles et al. 2010) . aVaDO found no difference in Os among the three arms, and median PFs was only marginally improved. RIBBON-1 evaluated bevacizumab in combination with the investigator's choice of one of several chemotherapy regiments. RIBBON-1 found a slight improvement in PFs favoring the arms containing bevacizumab (~1-3 months), but no difference in Os (Robert et al. 2011 ). a pooled analyses of these 3 trials (O'shaughnessy et al. 2010) concluded that bevacizumab along with chemotherapy improved PFs 6.7-9.2 mo (HR = 0.64, p < 0.0001), but did not change Os. Improving PFs, while adding toxicity, and failing to improve Os does not define a marginally effective therapy, but constitutes a harmful one. as such the FDa revoked bevacizumab's approval in metastatic breast cancer.
Conclusion
another way to conceptualize how a long sPP affects statistical power is simply to realize that small gains are harder to detect when Os is long. Increasing survival by 3 months from 3 to 6 is a 100 % gain, while increasing survival from 24 to 27 months is only a 13 % improvement. (Booth and eisenhauer 2012; Driscoll and Rixe 2009; Cheema and Burkes 2013) have criticized increasing use of PFs and argued that Os should remain the preferred endpoint, for indications with long sPP, improving Os has been asserted to be difficult and not worth the effort or expense (lebwohl et al. 2009 ). We disagree. the cost to society when ultimately ineffective practices gain widespread use is often an order of magnitude greater than the cost of conducting proper studies upfront (Prasad et al. 2012; Prasad and Cifu 2011) . Knowing that small gains in survival are real, especially when survival is long, remains best adjudicated by adequately powered trials, and not continued faith in PFs.
Conflict of interest None.
